Bli medlem
Bli medlem

Du är här


MorphoSys AG: MorphoSys to Present Data on Proprietary Programs at 20th Congress of the European Hematology Association

MorphoSys AG / MorphoSys to Present Data on Proprietary Programs at 20th
Congress of theEuropean Hematology Association . Processed and transmitted by
NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the
content of this announcement.
Substantial Data Packages on Lead Compounds MOR202 and MOR208

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced the
publication of three MorphoSys abstracts which were submitted to the
20thCongress of the European Hematology Association (EHA) to take place from
June 11 - 14 in Vienna, Austria. The abstracts include pre-clinical and
clinical data on the Company's proprietary drug candidate MOR202 from a Phase
1/2a study in patients with multiple myeloma and updated clinical data for
the MOR208 program.

"The progress of our cancer compounds MOR202 and MOR208 is increasingly
gaining visibility," commented Dr. Arndt Schottelius, Chief Development
Officer of MorphoSys AG. "We are looking forward to presenting our most
advanced cancer programs at the EHA congress, including efficacy data for
MOR202 from the Phase 1/2a study in multiple myeloma."

List of abstracts:

Abstract EHA-3357

A phase 1/2a study of the human anti-CD38 antibody MOR202 (MOR03087) in
relapsed or refractory multiple myeloma

The presentation will include the in the abstract described safety results and
additional first efficacy results. The oral presentation will take place on
Sunday, June 14, 09:00 - 09:15 am CEST.

Abstract EHA-3452

Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202,
a human CD38 antibody in combination with pomalidomide.

The poster presentation will take place on Saturday, June 13, 5:15 - 6:45 pm

Abstract #E990

A phase 2a study of single-agent MOR208, an Fc-optimized anti-CD19 antibody,
in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

The abstract will be on display on the e-poster screens from Friday, June 12,
09:30 am to Saturday, June 13, 6:45 pm CEST.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 90 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®,arYla
®and Ylanthia®and 100 billion high potentials®are registered trademarks of
MorphoSys AG.

Slonomics®is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications&IR

Mario Brkulj
Associate Director Corporate Communications&IR

Alexandra Goller
Manager Corporate Communications&IR

Jessica Rush
Manager Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404

Media Release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.